文献速递冠心病

一种解读早期试验的新方法显示:冠状动脉窦缩窄术可协同改善难治性心绞痛的症状、功能状态与生活质量

A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina.
PubMed 文献 · Heart · 2020-07-21

该研究为COSIRA试验的事后疗效分析,纳入104例CCS 3-4级难治性心绞痛患者,随机接受冠状动脉窦缩窄器或假手术。结果显示缩窄器组在症状、运动耐量和生活质量等多个领域达到预设的协同改善标准(组水平),支持将这一早期试验方法用于指导后续确证性试验。

要点

  • 冠状动脉窦缩窄器在症状、运动耐量和生活质量上协同改善,达到预设标准。
  • 该分析为早期试验解读提供了新方法,可辅助决策是否推进确证性试验。
  • 研究对象为不适合血运重建的CCS 3-4级难治性心绞痛患者。

核心结论

  • 在COSIRA试验的事后分析中,冠状动脉窦缩窄器相比假手术协同改善了难治性心绞痛患者的症状、功能状态和生活质量。

研究设计与样本

  • COSIRA试验的事后疗效分析,纳入104例CCS 3-4级难治性心绞痛患者,随机分为缩窄器组(n=52)和假手术组(n=52)。
  • 分析涵盖四个领域:症状(CCS心绞痛分级)、功能(总运动持续时间)、缺血(影像学)和健康相关生活质量,并为每个领域设定有意义的改变阈值。

主要发现

  • 缩窄器组在组水平达到预设的协同标准,症状改善0.59个CCS分级(95% CrI 0.22至0.95)。
  • 总运动持续时间增加27.9%(95% CrI 2.8%至59.8%)。
  • 生活质量稳定性评分提高11.2分(95% CrI 3.3至19.1),感知评分提高11.0分(95% CrI 3.3至18.7)。

关键数值与推荐

  • 主要终点定义为:缩窄器组在至少两个领域超过有意义阈值的概率≥80%(组水平分析),或缩窄器组平均疗效评分超过假手术组至少2分(患者水平分析)。

临床怎么用

  • 对于不适合血运重建的难治性心绞痛患者,冠状动脉窦缩窄器可能协同改善症状、功能和生活质量。
  • 协同分析方法可用于解读早期阶段试验,辅助决策是否推进至更大规模的确证性试验。

局限性

  • 本研究为COSIRA试验的事后分析,结果需在更大规模确证性试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduction of the coronary sinus was shown to improve angina in patients unsuitable for revascularisation. We assessed whether a percutaneous device that reduces the diameter of the coronary sinus improved outcomes across multiple endpoints in a phase II trial. METHODS: We conducted a novel analysis performed as a post hoc efficacy analysis of the COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial, which enrolled patients with Canadian Cardiovascular Society (CCS) class 3-4 refractory angina. We used four domains: symptoms (CCS Angina Scale), functionality (total exercise duration), ischaemia (imaging) and health-related quality of life. For all domains, we specified a meaningful threshold for change. The primary endpoint was defined as a probability of ≥80% that the reducer exceeded the meaningful threshold on two or more domains (group-level analysis) or that the average efficacy score in the reducer group exceeded the sham control group by at least two points (patient-level analysis). RESULTS: We randomised 104 participants to either a device that narrows to coronary sinus (n=52) or a sham implantation (n=52). The reducer group met the prespecified criteria for concordance at the group level and demonstrated improvement in symptoms (0.59 CCS grade, 95% credible interval (CrI)=0.22 to 0.95), total exercise duration (+27.9%, 95% CrI=2.8% to 59.8%) and quality of life (stability +11.2 points, 95% CrI=3.3 to 19.1; perception +11.0, 95% CrI=3.3 to 18.7). CONCLUSIONS: The reducer concordantly improved symptoms, functionality and quality of life compared with a sham intervention in patients with angina unsuitable for coronary revascularisation. Concordant analysis such as this one can help interpret early phase trials and guide the decision to pursue a clinical programme into a larger confirmatory trial. TRAIL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT01205893.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Jolicoeur EM, Verheye S, Henry TD, et al. A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina. Heart. 2020. PMID: 32719097. doi:10.1136/heartjnl-2020-316644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。